X 1. In house marketing and distribution: Kirkov X 2. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million X 3. Full ownership of Adderall IR $335 Million —4. Full ownership of Adderall XR $ 1.56 Billion —5. Generic Concerta- $1.2 BILLION —6. Generic Vyvanse- $5.3 BILLION —7. Vigabatrin —8. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million —9. Patented Unique ADF (w/o naltrexone)-- NDA —10. Mikah ANDA —11. Undisclosed —12. Antimetabolite ANDA- Methotrexate -$600 Million —13. Undisclosed Antimetabolite ANDA- $42 Million —14. Prasco/Burel Adderall agreement —15. Dexcel partnership approval by Israeli health for European distribution
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.